INS and Cognitive impairment: Indeed, a small phase II trial (n = 30, no cognitive impairment) has commenced that compares three different devices for the delivery of intranasal insulin at two doses (20 IU and 40 IU) (URL accessed on 4 March 2022, www.alzforum.org/therapeutics/nasal-insulin).